British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005

Smith, C. H., Anstey, Alexander Vincent ORCID: https://orcid.org/0000-0002-6345-4144, Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D., Finlay, Andrew Yule ORCID: https://orcid.org/0000-0003-2143-1646, Grifitths, C. E. M., Jackson, K., McHugh, N. J., McKenna, K. E., Reynolds, N. J. and Ormerod, A. D. 2005. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. British Journal of Dermatology 153 (3) , pp. 486-497. 10.1111/j.1365-2133.2005.06893.x

Full text not available from this repository.

Abstract

Psoriasis is a common, persistent, relapsing inflammatory skin disease that can be associated with significant morbidity. Quality of life studies in psoriasis reveal a negative impact on patients comparable with that seen in cancer, arthritis and heart disease.1–5 Patients with severe disease constitute approximately 20–30% of all patients with psoriasis, often require systemic treatment, and represent a major economic burden to the Health Service. All standard systemic therapies for severe disease are associated with the potential for major long-term toxicity, many are expensive, and a proportion of patients has treatmentresistant disease.6 Biological therapies or ‘biologics’ describe agents designed to block specific molecular steps important in the pathogenesis of psoriasis and have emerged over the last 3–5 years as potentially valuable alternative therapeutic options. Currently, biological therapies for psoriasis comprise two main groups: (i) agents targeting the cytokine tumour necrosis factor (TNF)-a (e.g. etanercept, infliximab, adalimumab) and (ii) agents targeting T cells or antigen-presenting cells (e.g. efalizumab, alefacept). Two of these, etanercept (Enbrel) and efalizumab (Raptiva) were licensed in 2004 in the U.K. for patients with moderate to severe psoriasis.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RL Dermatology
Uncontrolled Keywords:	biologics, efalizumab, etanercept, guideline, infliximab, psoriasis
Publisher:	Wiley-Blackwell
ISSN:	0007-0963
Last Modified:	21 Oct 2022 09:35
URI:	https://orca.cardiff.ac.uk/id/eprint/36976

Citation Data

Cited 269 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item